387 related articles for article (PubMed ID: 29221792)
1. The serotonin hallucinogen 5-MeO-DMT alters cortico-thalamic activity in freely moving mice: Regionally-selective involvement of 5-HT
Riga MS; Lladó-Pelfort L; Artigas F; Celada P
Neuropharmacology; 2018 Nov; 142():219-230. PubMed ID: 29221792
[TBL] [Abstract][Full Text] [Related]
2. The serotonergic hallucinogen 5-methoxy-N,N-dimethyltryptamine disrupts cortical activity in a regionally-selective manner via 5-HT(1A) and 5-HT(2A) receptors.
Riga MS; Bortolozzi A; Campa L; Artigas F; Celada P
Neuropharmacology; 2016 Feb; 101():370-8. PubMed ID: 26477571
[TBL] [Abstract][Full Text] [Related]
3. The natural hallucinogen 5-MeO-DMT, component of Ayahuasca, disrupts cortical function in rats: reversal by antipsychotic drugs.
Riga MS; Soria G; Tudela R; Artigas F; Celada P
Int J Neuropsychopharmacol; 2014 Aug; 17(8):1269-82. PubMed ID: 24650558
[TBL] [Abstract][Full Text] [Related]
4. Behavioral and pharmacokinetic interactions between monoamine oxidase inhibitors and the hallucinogen 5-methoxy-N,N-dimethyltryptamine.
Halberstadt AL
Pharmacol Biochem Behav; 2016 Apr; 143():1-10. PubMed ID: 26780349
[TBL] [Abstract][Full Text] [Related]
5. Potentiation of 5-methoxy-N,N-dimethyltryptamine-induced hyperthermia by harmaline and the involvement of activation of 5-HT1A and 5-HT2A receptors.
Jiang XL; Shen HW; Yu AM
Neuropharmacology; 2015 Feb; 89():342-51. PubMed ID: 25446678
[TBL] [Abstract][Full Text] [Related]
6. Differential contributions of serotonin receptors to the behavioral effects of indoleamine hallucinogens in mice.
Halberstadt AL; Koedood L; Powell SB; Geyer MA
J Psychopharmacol; 2011 Nov; 25(11):1548-61. PubMed ID: 21148021
[TBL] [Abstract][Full Text] [Related]
7. Hallucinogen-like actions of 5-methoxy-N,N-diisopropyltryptamine in mice and rats.
Fantegrossi WE; Harrington AW; Kiessel CL; Eckler JR; Rabin RA; Winter JC; Coop A; Rice KC; Woods JH
Pharmacol Biochem Behav; 2006 Jan; 83(1):122-9. PubMed ID: 16460788
[TBL] [Abstract][Full Text] [Related]
8. Serotonin 5-HT
Gener T; Tauste Campo A; Alemany-González M; Nebot P; Delgado-Sallent C; Chanovas J; Puig MV
Neuropharmacology; 2019 Nov; 158():107743. PubMed ID: 31430459
[TBL] [Abstract][Full Text] [Related]
9. The paradox of 5-methoxy-N,N-dimethyltryptamine: an indoleamine hallucinogen that induces stimulus control via 5-HT1A receptors.
Winter JC; Filipink RA; Timineri D; Helsley SE; Rabin RA
Pharmacol Biochem Behav; 2000 Jan; 65(1):75-82. PubMed ID: 10638639
[TBL] [Abstract][Full Text] [Related]
10. The roles of 5-HT1A and 5-HT2 receptors in the effects of 5-MeO-DMT on locomotor activity and prepulse inhibition in rats.
Krebs-Thomson K; Ruiz EM; Masten V; Buell M; Geyer MA
Psychopharmacology (Berl); 2006 Dec; 189(3):319-29. PubMed ID: 17013638
[TBL] [Abstract][Full Text] [Related]
11. Dual actions of 5-MeO-DIPT at the serotonin transporter and serotonin 5-HT
Hagino Y; Hall FS; Uhl GR; Sora I; Ikeda K
Neuropsychopharmacol Rep; 2021 Mar; 41(1):91-101. PubMed ID: 33547882
[TBL] [Abstract][Full Text] [Related]
12. Clozapine Reverses Phencyclidine-Induced Desynchronization of Prefrontal Cortex through a 5-HT(1A) Receptor-Dependent Mechanism.
Kargieman L; Riga MS; Artigas F; Celada P
Neuropsychopharmacology; 2012 Feb; 37(3):723-33. PubMed ID: 22012474
[TBL] [Abstract][Full Text] [Related]
13. Enhanced effects of amphetamine but reduced effects of the hallucinogen, 5-MeO-DMT, on locomotor activity in 5-HT(1A) receptor knockout mice: implications for schizophrenia.
van den Buuse M; Ruimschotel E; Martin S; Risbrough VB; Halberstadt AL
Neuropharmacology; 2011; 61(1-2):209-16. PubMed ID: 21501627
[TBL] [Abstract][Full Text] [Related]
14. Modification of 5-methoxy-N,N-dimethyltryptamine-induced hyperactivity by monoamine oxidase A inhibitor harmaline in mice and the underlying serotonergic mechanisms.
Jiang XL; Shen HW; Yu AM
Pharmacol Rep; 2016 Jun; 68(3):608-15. PubMed ID: 26977821
[TBL] [Abstract][Full Text] [Related]
15. In vivo actions of aripiprazole on serotonergic and dopaminergic systems in rodent brain.
Bortolozzi A; Díaz-Mataix L; Toth M; Celada P; Artigas F
Psychopharmacology (Berl); 2007 Apr; 191(3):745-58. PubMed ID: 17265076
[TBL] [Abstract][Full Text] [Related]
16. Contribution of serotonin receptor subtypes to hallucinogenic activity of 25I-NBOMe and to its effect on neurotransmission.
Herian M; Wojtas A; Sobocińska MK; Skawski M; González-Marín A; Gołembiowska K
Pharmacol Rep; 2020 Dec; 72(6):1593-1603. PubMed ID: 33174181
[TBL] [Abstract][Full Text] [Related]
17. Structural pharmacology and therapeutic potential of 5-methoxytryptamines.
Warren AL; Lankri D; Cunningham MJ; Serrano IC; Parise LF; Kruegel AC; Duggan P; Zilberg G; Capper MJ; Havel V; Russo SJ; Sames D; Wacker D
Nature; 2024 Jun; 630(8015):237-246. PubMed ID: 38720072
[TBL] [Abstract][Full Text] [Related]
18. [On the Functional Cross-Talk between Brain 5-HT1A and 5-HT2A Receptors].
Naumenko VS; Bazovkina DV; Kondaurova EM
Zh Vyssh Nerv Deiat Im I P Pavlova; 2015; 65(2):240-7. PubMed ID: 26080602
[TBL] [Abstract][Full Text] [Related]
19. Modification of the effects of 5-methoxy-N,N-dimethyltryptamine on exploratory behavior in rats by monoamine oxidase inhibitors.
Halberstadt AL; Buell MR; Masten VL; Risbrough VB; Geyer MA
Psychopharmacology (Berl); 2008 Nov; 201(1):55-66. PubMed ID: 18604652
[TBL] [Abstract][Full Text] [Related]
20. Characterization of a novel effect of serotonin 5-HT1A and 5-HT2A receptors: increasing cGMP levels in rat frontal cortex.
Regina MJ; Winter JC; Rabin RA
Neuropharmacology; 2003 Dec; 45(8):1041-9. PubMed ID: 14614947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
